REGENXBIO Inc. (RGNX) — Inside-Filings

Sentiment-Signal

14,7

Stark Bearisch

Composite Score (0–100)

Insider (25%)

Keine Insider-Käufe

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Stammdaten

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Unternehmen & Branche

Name	REGENXBIO Inc.
Ticker	RGNX
CIK	0001590877
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2836 · Biological Products, (No Diagnostic Substances)

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	448,6 Mio. USD
Beta	1,13
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	170,441,000	-193,878,000	-3.76	453,032,000	102,733,000
2025-09-30	10-Q	29,733,000	-61,941,000	-1.20	525,203,000	161,452,000
2025-06-30	10-Q	21,359,000	-70,871,000	-1.38	581,027,000	213,679,000
2025-03-31	10-Q	89,012,000	6,083,000	0.12	490,929,000	274,197,000
2024-12-31	10-K	83,328,000	-227,102,000	-4.59	465,989,000	259,651,000
2024-09-30	10-Q	24,197,000	-59,597,000	-1.17	519,114,000	301,416,000
2024-06-30	10-Q	22,295,000	-52,989,000	-1.05	569,379,000	348,267,000
2024-03-31	10-Q	15,622,000	-63,330,000	-1.38	629,215,000	390,666,000
2023-12-31	10-K	90,242,000	-263,494,000	-6.02	573,970,000	311,742,000
2023-09-30	10-Q	28,914,000	-61,868,000	-1.41	633,786,000	363,100,000
2023-06-30	10-Q	19,977,000	-72,061,000	-1.66	682,458,000	405,855,000
2023-03-31	10-Q	19,138,000	-66,676,000	-1.53	747,830,000	465,139,000
2022-12-31	10-K	112,724,000	-280,321,000	-6.50	833,268,000	516,195,000
2022-09-30	10-Q	26,512,000	-75,484,000	-1.75	883,793,000	563,824,000
2022-06-30	10-Q	32,649,000	-68,179,000	-1.58	953,444,000	630,519,000
2022-03-31	10-Q	22,218,000	-76,723,000	-1.79	1,025,368,000	689,669,000
2021-12-31	10-K	470,347,000	127,840,000	2.91	1,113,904,000	764,298,000
2021-09-30	10-Q	30,773,000	-58,405,000	-1.37	800,395,000	461,414,000
2021-06-30	10-Q	22,035,000	-57,639,000	-1.36	836,402,000	507,245,000
2021-03-31	10-Q	18,884,000	-50,139,000		879,442,000	554,504,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ	Trend
2025-10-09	Simpson Curran	Director, Officer, Chief Executive Officer	Open Market Sale	-20,811	12.62	-262,634.82	-154,9%
2025-09-29	Simpson Curran	Director, Officer, Chief Executive Officer	Open Market Sale	-7,624	10.03	-76,468.72	-45,1%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.